

VUR patients with continuous antibiotic prophylaxis had **6.4x** the odds of developing a multidrug-resistant infection.¹

1,460 The number of antibiotics for 4 years of prophylactic VUR treatment (assuming 1 dose/day)

43.8% Resolution rate of VUR grade III (unilateral 25-60 mos.) at 4 years²

Use of antibiotic prophylaxis in VUR treatment resulted in **79%** more UTIs when compared to treatment with Deflux³

Why Wait?

Deflux was proven effective in up to **93%** of children, with no FUTIs after one injection,⁴ and has a **94%** long-term parental satisfaction rate.⁵

For more information, contact
1.844.350.9656 or visit **Deflux.com**

Deflux®

The percent chance of reflux resolution after specified number of years (95% confidence interval)^{2*}

RISK CATEGORY	1 YEAR	2 YEARS	3 YEARS	4 YEARS	5 YEARS
age in months; number of patients on which estimates are based					
Grade I[†] N=15	39.3 (24.6-51.1)	63.1 (43.2-76.1)	77.6 (57.2-88.3)	86.4 (67.7-94.3)	91.8 (75.7-97.2)
Grade II[†] N=250	28 (24.1-31.7)	48.1 (42.3-53.4)	62.7 (56.2-68.1)	73.1 (66.8-78.2)	80.6 (74.8-85.1)
Grade III, unilateral, age 0-24 N=27	21.4 (10.8-30.8)	38.2 (20.4-52.1)	51.5 (29-66.8)	61.9 (36.6-77.1)	70 (43.5-84.1)
Grade III, unilateral, age 25-60 N=27	13.4 (4.6-21.4)	25 (8.9-38.3)	35.1 (13.1-51.5)	43.8 (17.1-61.9)	51.3 (20.9-70.1)
Grade III, unilateral, age 61-120 N=15	10.8 (3.5-17.5)	20.5 (6.9-32)	29.1 (10.2-43.9)	36.7 (13.4-53.8)	43.6 (16.5-61.9)
Grade III, bilateral, age 0-24 N=62	12.7 (7-18.1)	23.8 (13.5-32.9)	33.5 (19.5-45)	41.9 (25.1-55)	49.3 (30.3-63.1)
Grade III, bilateral, age 25-60 N=53	7 (3.1-10.8)	13.5 (6.1-20.4)	19.6 (9-28.9)	25.2 (11.8-36.6)	30.5 (14.6-43.4)
Grade III, bilateral, age 61-120 N=14	2.6 (0.7-4.5)	5.2 (1.4-8.8)	7.7 (2.1-13)	10.1 (2.8-16.9)	12.5 (3.5-20.7)
Grade IV, unilateral[‡] N=28	16.1 (8.5-23.1)	29.7 (16.4-40.8)	41 (23.5-54.5)	50.5 (30-65)	58.5 (36-73.1)
Grade IV, bilateral[‡] N=96	4.5 (1-7.9)	6.4 (2-15.1)	7.8 (3-21.8)	8.9 (4-28)	9.9 (4.9-33.7)

* The yearly rate of reflux resolution remains constant for each group

† No difference shown by age or laterality (unilateral/bilateral); therefore, these categories were combined

‡ Estimates only apply to the time of diagnosis and are not age specific.

References

- Selekman RE, Shapiro DJ, Boscardin J, et al. Uropathogen resistance and antibiotic prophylaxis: a meta-analysis. *Pediatr.* 2018;142(1):1-8
- Elder JS, Peters CA, Arant BS, et al. AUA pediatric vesicoureteral reflux clinical guidelines panel: The management of primary vesicoureteral reflux in children. *American Urological Association Education and Research, Inc.* 1997.
- Hensle TW, Hyun G, Grogg AL, et al. Assessing the effectiveness of endoscopic injection in treating patients with vesicoureteral reflux for the reduction of urinary tract infections. *2006 Annual Meeting of American Academy of Pediatrics.* Atlanta, GA.
- Kalisvaart JF, Scherz HC, Cuda S, Kaye JD, Kirsch AJ. Intermediate to long-term follow-up indicates low risk of recurrence after double HIT endoscopic treatment for primary vesicoureteral reflux. *J Pediatr Urol.* 2012;9(4):359-365.
- Lightfoot M, Bilgutay AN, Tolin N, et al. Long-term clinical outcomes and parental satisfaction after dextranomer/hyaluronic acid (Dx/HA) injection for primary vesicoureteral reflux. *Frontiers in Pediatrics.* 2019;7(392):1-9.

Palette Life Sciences
Medical Information Department

T: 844.350.9656
F: 510.595.8183
E: palettemc@dlss.com

Deflux is a registered trademark.
© 2020 Palette Life Sciences, Inc.
All Rights Reserved. APM062B